Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a research note issued on Thursday,Benzinga reports. They presently have a $28.00 target price on the stock. JMP Securities’ target price suggests a potential upside of 244.15% from the stock’s current price.

A number of other equities analysts have also weighed in on KURA. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Wedbush lifted their target price on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Thursday. Bank of America cut their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, HC Wainwright upped their price target on Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA traded down $0.91 on Thursday, reaching $8.14. The company’s stock had a trading volume of 2,460,447 shares, compared to its average volume of 1,770,848. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The stock has a market capitalization of $632.66 million, a P/E ratio of -3.45 and a beta of 0.78. The stock’s 50-day moving average is $8.83 and its two-hundred day moving average is $15.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period in the previous year, the company earned ($0.50) EPS. As a group, sell-side analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Kura Oncology

Large investors have recently modified their holdings of the business. nVerses Capital LLC purchased a new position in Kura Oncology in the third quarter valued at about $25,000. China Universal Asset Management Co. Ltd. grew its position in shares of Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after buying an additional 1,750 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the 3rd quarter worth about $146,000. US Bancorp DE grew its stake in Kura Oncology by 184.5% in the fourth quarter. US Bancorp DE now owns 22,104 shares of the company’s stock worth $193,000 after purchasing an additional 14,335 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Kura Oncology in the third quarter valued at about $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.